• On October 10, 2025, Legend Biotech announced that the U.S. FDA approved a label update for CARVYKTI® to reflect statistically significant overall survival benefits in relapsed and refractory multiple myeloma, as shown in the Phase 3 CARTITUDE-4 study, and incorporated new safety warnings, including immune effector cell-associated enterocolitis and JC virus reactivation.
• This development not only highlights longer survival outcomes for patients but also underscores the evolving safety landscape and responsibilities for prescribers using CARVYKTI.
• We'll now examine how the FDA's endorsement of CARVYKTI's survival benefit and updated safety profile influences Legend Biotech's investment narrative.

These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Legend Biotech Investment Narrative Recap

For investors considering Legend Biotech, belief in the company’s ability to expand CARVYKTI’s reach and deliver durable clinical benefits is fundamental. The FDA’s label update, confirming a survival benefit while adding serious safety warnings, may strengthen the argument for broader use in the near term, possibly the single most important catalyst, but also brings the principal risk of heightened safety scrutiny more sharply into focus.

Among recent company developments, the June 2025 updates to CARVYKTI’s Risk Evaluation and Mitigation Strategy (REMS) stand out, aimed at easing patient monitoring and access. This directly relates to regulatory catalysts that could either accelerate or inhibit uptake of CARVYKTI, depending on the balance of efficacy and safety in ongoing real-world use.

In contrast, investors should be aware that new safety risks, such as immune effector cell-associated enterocolitis and JC virus reactivation, may impact the commercial trajectory...

Legend Biotech's narrative projects $2.3 billion revenue and $632.7 million earnings by 2028. This requires 42.3% yearly revenue growth and a $958 million earnings increase from -$325.3 million.

Uncover how Legend Biotech's forecasts yield a $76.00 fair value, a 139% upside to its current price.

Exploring Other Perspectives

Six perspectives from the Simply Wall St Community put fair value for Legend Biotech between US$40.82 and US$123.68 per share. With profit growth and pipeline risks in play, you can see how market views on future performance can be very different, explore a spectrum of opinions to weigh your next step.

Explore 6 other fair value estimates on Legend Biotech - why the stock might be worth over 3x more than the current price!

Build Your Own Legend Biotech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Legend Biotech research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.